drugset / Trial / NCT00720421

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

NCT00720421

Phase 1 Completed 16 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to determine the effects of the compound AZD7325 as compared to lorazepam on sleepiness, concentration and brain activity.

Timeline

Start
2008-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule 1 mg Oral
Subject AZD7325 Small molecule 10 mg Oral
Subject Lorazepam Small molecule 1 mg Oral

Indications

No indication recorded.